BURLINGAME, Calif.--(BUSINESS WIRE)--Pyxis One, a California-based tech startup that aims to revolutionize marketing and consumer intelligence by providing an all-in-one, codeless AI platform, closed ...

Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head and ...

Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

During the first quarter of this year, the time charter equivalent rate was approximately $23,500 per day per vessel. That’s slightly lower than I had anticipated but the total revenue in the first ...

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the ...

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...

BOSTON, March 23, 2026 (GLOBE NEWSWIRE)-- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a ...